Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

Context: There is much debate surrounding the choice of which patient should be submitted
to postsurgical remnant radioiodine remnant ablation (RRA), particularly in low-risk (LR) and …

Background The aim of this study is to compare the effectiveness of 131 I therapy between
three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation …

Objective This study was carried out to confirm whether patients with intermediate-risk
differentiated thyroid cancer (DTC) could benefit from initial 131 I ablation and to identify the …

Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
patients with different risk of recurrence [5]. The benefits of postoperative 131I differs …

Background: Papillary thyroid cancer (PTC) represents most of cases of differentiated thyroid
cancers. Thyroidectomy followed by radioactive iodine (RAI) remnant ablation represent the …

The study was to evaluate the effect of radioactive iodine (RAI) treatment application time
and clinical, histopathological factors on ablation success in patients with operated papillary …

Whether to conduct remnant ablation or adjuvant radioactive iodine (RAI) therapy in patients
with intrathyroidal differentiated thyroid carcinoma (DTC), sized 1.1–4 cm, is debated. We …

Background Patients with differentiated thyroid cancer (DTC) who undergo total
thyroidectomy are candidates for adjuvant radioactive iodine ablation (RAI). RAI is used to …

Most patients with newly diagnosed differentiated thyroid carcinoma have tumours with low
risk of mortality and recurrence. Standard therapy has been total or near total thyroidectomy …